tbuckley/cabot-search huggingface dataset:
Therapeutic efficacy of an oncolytic adenovirus monitored by in vivo imaging of an ovarian cancer model
Authors: Y. Tsuruta, L. Pereboeva, D. T. Rein, M. Breidenbach, D. T. Curiel
Journal: Journal of Clinical Oncology (2006)

10061 Background: Although a number of advances in ovarian cancer treatment have occurred in the last decade, most patients will experience a recurrence after standard therapies. Recently, virotherapy has been proposed as a new therapeutic approach for ovarian cancer. Conditionally replicative adenovirus (CRAd) contains tumor-specific promoters that restrict virus replication to cancer cells and has shown particular promise as oncolytic viral agents. However, the lack of a tumor-volume monitoring system hinders the evaluation of CRAd impact on cancer treatment. Therefore, methods for analyzing CRAd efficacy and tumor response are required. Mesothelin, a cell surface glycoprotein, is overexpressed in ovarian cancer but not in normal ovarian tissues. The purpose of this study was to explore the therapeutic utility of a mesothelin promoter-based CRAd in a murine model of ovarian cancer, using a non-invasive biological imaging system. Methods: We constructed a mesothelin promoter based CRAd which also contains a modified fiber (Ad5/3 fiber) previously shown to improve infectivity of many ovarian cancer cells (Ad5/3MSLN). Viral replication and oncolysis were assessed in a panel of ovarian cancer cell lines. To test the oncolytic efficacy of Ad5/3MSLN in murine model, firefly luciferase-expressing SK-OV-3-luc cells were injected intraperitoneally (i.p.), followed by an i.p. injection of viruses. Then, bioluminescence imaging of tumor luciferase activity was carried out. Results: Ad5/3MSLN achieved up to 10,000-fold higher cell killing effect and up to 120-fold higher levels of viral replication in all ovarian cancer cell lines tested, compared to wild type Ad5. In vivo tumor imaging confirmed that Ad5/3MSLN significantly inhibited tumor growth, while the untreated mice had rapid tumor growth (p&lt;0.05). Survival with Ad5/3MSLN was significantly enhanced when compared with no virus, or wild type Ad5-treated group (p&lt;0.05). Conclusions: The robust replication, oncolysis, and in vivo therapeutic efficacy of Ad5/3MSLN demonstrated that this CRAd is a promising candidate for treating ovarian cancer. Importantly, we have established an in vivo non-invasive imaging system, which has allowed repeated and longitudinal measurements of tumor growth after CRAd treatment. No significant financial relationships to disclose.
Imported cholera with acute renal failure after a short business-trip to the Philippines, Germany, October 2015
Authors: Günther Slesak, Ralf Fleck, Daniela Jacob, Roland Grunow, Johannes Schäfer
Journal: Eurosurveillance (2016)

A German businessman developed acute watery diarrhoea after a three-day trip to the Philippines. He was admitted with severe hypotension and acute renal failure, but recovered with rapid rehydration. Vibrio cholerae O1 serotype Ogawa was isolated. Physicians need to be aware of endemic cholera in Asia including the Philippines and consider this in their pre-travel advice.
Building a Learning Marijuana Surveillance System
Authors: Sharon Levy, Elissa R. Weitzman
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Resilience to chronic stress is mediated by noradrenergic regulation of dopamine neurons
Authors: Elsa Isingrini, Léa Perret, Quentin Rainer, Bénédicte Amilhon, Elisa Guma, Arnaud Tanti, Garance Martin, Jennifer Robinson, Luc Moquin, Fabio Marti, Naguib Mechawar, Sylvain Williams, Alain Gratton, Bruno Giros
Journal: Nature Neuroscience (2016)
The difference in implantation quality between loose seed and variable spacing strand seeds in the field of prostate brachytherapy.
Authors: Pigné Grégoire, Pigné Grégoire, Tanguy Ronan, Ribouton Julien, Alain Ruffion, Olivier Chapet
Journal: Journal of Clinical Oncology (2014)

252 Background: Concordance between intraoperative and postoperative dosimetry is a well-known marker of implant quality in prostate brachytherapy. The aim of the study was to evaluate if the use of variable distance strand seeds allows an improvement in the quality of the post implantation dosimetry. Methods: Before December 2010, an iodine 125 loose-seed technique was used for prostate brachytherapy. Since this date, patients have been treated with new variable distance strand seeds (ProLink; Bard). Post implant dosimetry was compared to intraoperative dosimetry in 30 patients treated with loose seeds and 29 patients treated with strand seeds. The prescribed dose was 145Gy. Variations of dosimetric parameters were used to set the two techniques against one another: prostate V100 and D90 and rectum V145 and V160. Results: There was a significant difference between intraoperative and postoperative V100 and D90 for all 59 patients: V100 preop-postop: mean 6,65% +/- SD 4,5; D90 preop-postop: 18,73Gy +/- SD 15 (p&lt;0,0001). This dosimetric difference between pre and post-operative dosimetry is more important using loose seeds brachytherapy: V100 preop-postop: 9,5% +/- SD 4,1 vs 3,7% +/- SD 2,7 for loose seeds and strand seeds respectively (p&lt;0,0001), and D90 preop-postop: 27,9Gy +/-SD 13,6 vs 9,2Gy +/- SD 9,7 for loose seeds and strand seeds respectively (p&lt;0,0001). For V145 rectum and V160 rectum, dosimetric difference wasn't significant: V145 rectum preop-postop: -0,9% +/- SD 1,4 with stranded seeds vs. -1,6% +/- SD 2,1 with loose seeds (p=0,14) and V160 rectum pre-postop: -0,5% +/- SD 0,8 with strand seeds vs. -0,5% +/- SD 0,8 with loose seeds (p=0,16). Conclusions: Stranded seeds implantation increases the quality of implantation by reducing the dosimetric difference (V100 and D90) between intra and post-operative dosimetry to a maximum of 6% and 7% vs. more than 20% with loose seed implantation. Moreover, this technique doesn’t seem to modify the risk of rectal toxicity. This achievement in implantation and dosimetric quality might lead to a gain in clinical results.
Effect of OVA activated tolerogenic mouse bone marrow dendritic cells on the production of IL-17 in vitro
Authors: Yi Huang, Yan Zhao, Youlan Zhang, Changzheng Wang
Journal: European Respiratory Journal (2013)

Dendritic cells induce and regulate T cell responses, and tolerogenic dendritic cells (DCs) can promote the development of regulatory T cells with suppressive activity. 1,25-dihydroxyvitamin D3 (1, 25(OH)2D3) is a secosteroid hormone that can cause tolerogenic dendritic cells (tDCs).However, the effect of tDCs activated by OVA on the production of interleukin (IL)-10 and IL-17 has not been well understood. We studied tDC effect on the production of IL-10 and IL-17 by using 1,25(OH)2D3-treated mouse bone marrow-derived immature dendritic cells (D3/imDC) exposed to ovalbumin (OVA)(OVA-D3/imDC) co-cultured with allogeneic naive CD4+T cells in vitro. First, we identified the phenotypes of the OVA-D3/imDCs. Then the capacity of OVA-D3/imDCs production of IL-10 and IL-17 were verified through analysis of the production of IL-17 and IL-10 in co-culture supernatant. OVA-D3/imDCs displayed a semi-mature phenotype through up-regulation of CD86 and MHC II and inhibition of allogeneic CD4+T cells proliferations. OVA-D3/imDCs promoted IL-10 secretion and inhibited IL-2 secretion. Co-culture of OVA-D3/imDCs with naive CD4+T cells induced CD4+Foxp3+Tregs. More importantly, OVA-D3/imDCs co-cultured with allogeneic naive CD4+T cells decreased IL-17 levels in co-culture supernatant; However, OVA-D3/imDCs co-cultured with allogeneic naive CD4+T cells enhanced IL-10 levels in co-culture supernatant. Our results suggested OVA-activated tolerogenic mouse bone marrow dendritic cells have ability to suppress the production of IL-17 and promote the production of IL-10.
Visa changes could lead to hundreds of doctors leaving the NHS, warns BMA
Authors: Abi Rimmer
Journal: BMJ (2016)

Proposed changes to visa rules could lead to hundreds of UK trained doctors leaving the NHS each year, the BMA has warned.

In a letter to the Home Office Mark Porter, chair of the BMA, said that recommendations for changes to visa rules made by the Migrations Advisory Committee could harm the medical workforce.1 In the letter to immigration minister James Brokenshire, Porter asked whether the Home Office would consider giving specific exemptions for the NHS.2

The BMA said that it was worried that UK trained international doctors, of which there are around …
Efficacy of Neoadjuvant Chemotherapy with Doxorubicin Plus Ifosfamide for Intermediate to High-Risk Soft Tissue Sarcomas
Authors: Kohichi Takada, Shogo Miura, Rishu Takimoto, Yusuke Kamihara, Satoshi Iyama, Yutaka Okagawa, Yasushi Sato, Toshihiko Yamashita, Tadashi Hasegawa, Junji Kato
Journal: Annals of Oncology (2014)
Phase II capecitabine and gemcitabine fixed dose rate (FDR) in patients with advanced pancreatic cancer
Authors: G. Tonini, B. Vincenzi, E. Vasile, V. Catalano, V. Virzì, A. Fontana, S. Intagliata, G. Catalano, A. Falcone, D. Santini
Journal: Journal of Clinical Oncology (2009)

e15530 Background: The aims of this phase II trial are to determine the activity and the safety of the new combination modality with Gemcitabine fixed dose rate (FDR) infusion and Capecitabine in patients with advanced pancreatic cancer. Methods: Patients with unresectable pancreatic cancer who had pathologically confirmed adenocarcinoma, no prior chemotherapy, ECOG PS &lt; 2 and measurable disease were enrolled. Gemcitabine (800 mg/mq IV infused in 80 minutes on days 1 and 8) and Capecitabine (650 mg/mq orally twice daily for 14 days) were administered and repeated every 21 days. Results: 47 patients were enrolled between January 2004 and October 2008. Median age was 66 (range: 37–79), 18 female and 29 male. A total of 299 cycles were administered, median cycles for patient were 6 (range: 1–17). CR was observed in one patient (2.1 %) and 10 patients achieved PR (21.3 %) giving an overall response rate of 23.4 % in intention-to-treat population. 22 pts (46.8 %) had stable disease obtaining an overall tumour control of 70.2 %. The median time to progression was 5.2 months (95 % CI, 2.4–7.6); the median overall survival was 8.4 months (95 % CI, 5.5–20). Grade 3–4 neutropenia was observed in 29.8 % of subjects, thrombocytopenia in 6.4 %. Grade 1–2 non-hematological toxicities were asthenia (61.7 %), diarrhea (29.8%), stomatitis (29.8 %) and hand foot syndrome (2.1 %). There were no treatment-related deaths. Gemcitabine was skipped at least once/reduced in 51/10.6 % of the patients, respectively. Capecitabine was skipped at least once/reduced in 16/8 % of the patients, respectively. Conclusions: The combination of FDR Gemcitabine and Capecitabine with this modality of infusion is feaseble, safe and seems to be active. No significant financial relationships to disclose.
18F]-FDG-PET in clinical stage I and II non-seminomatous germ cell tumors: First results of the German Multicenter Trial
Authors: M. de Wit, M. Hartmann, J. Kotzerke, M. Wirth, W. Brenner, D. Hellwig, J. Lehmann, R. Heicappell, C. Bokemeyer, R. Bares
Journal: Journal of Clinical Oncology (2005)

4504 Purpose:Aim of this study was to evaluate FDG-PET for staging of retroperitoneal lymph nodes in patients with newly diagnosed non-seminomatous germ cell cancer (NSGCT). Methods: Patients with primary diagnosis of stage I/II NSGCT scheduled for primary RLA were included. 70 patients aged 18–55 (mean age: 31 years) treated in 13 centers were examined with concurrent FDG-PET and CT. FDG-PET was performed in fasting state, emission scans started 45’ following injection of FDG. Image reconstruction was by filtered back projection or iterative algorithms. All PET-scanners were calibrated using the same phantom. The presented data are based on visual scan analysis. All patients underwent primary RLA. Thus, all results were validated by histology. Results: 39 patients had pathological stage I, 31 stage pII, 16 of them stage IIA. Histology of the primary tumor included 41 mixed germ cell tumors, 10 embryonal carcinoma, 10 embryonal carcinoma with teratoma, 5 chorioncarcinoma, 3 teratoma with malignant areas and 1 mature teratoma. Correct staging by PET was achieved in 55 of 70 (78%) compared with correct CT-staging in 49 of 70 patients (70%). 33 patients demonstrated retroperitoneal lymph nodes in CT scan, 22 had pathological involvement of lymph nodes. Out of 37 patients with cN0 10 had positive nodes. Thus CT had a sensitivity, specificity and accuracy of 69, 71, and 70%. Positive predictive value (PPV) and negative predictive value (NPV) were 69 and 73%. 21 of 25 patients with a positive FDG-PET turned out to have viable tumor while in 34 out of 45 patients with a negative scan no lymph node metastases were found. FDG-PET turned out to show a sensitivity, specificity and accuracy of 65, 89, and 79%. PPV and NPV were 84 and 76%. Conclusion: FDG-PET as primary staging for germ cell cancer is more accurate than CT and has a high specificity, but the false negative group is still high. No significant financial relationships to disclose.
HEART STRAIN AND WEAK HEARTS
Authors: J J Levick
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Empiric antibiotics for an elevated PSA: A randomized, prospective multi-institutional trial.
Authors: Michael Christopher Large, Glenn Scott Gerber, Joseph Atkins Pettus, John Smith, Ofer Yossepowitch, Norm D. Smith, Shilajit Kundu, Jay D. Raman, Scott E. Eggener
Journal: Journal of Clinical Oncology (2012)

32 Background: The impact of an empiric course of antibiotics for a newly elevated PSA in an asymptomatic male is poorly understood. Methods: Men of any age with a PSA &gt; 2.5 ng/ml and normal digital rectal examination undergoing their first prostate biopsy were recruited from six medical centers. Patients with previous biopsy, prostate cancer, urinary tract infection (UTI) or prostatitis within the prior year, antibiotic use within one month, 5−alpha reductase inhibitor use, allergy to fluoroquinolones or clinical suspicion of UTI were excluded. Men were randomized to two weeks of ciprofloxacin 500 mg twice daily or no antibiotic. A PSA was obtained 21−45 days following randomization and immediately prior to prostate biopsy. All patients received institution−specific prophylactic peri−procedural antibiotics. Primary endpoint was change in PSA between baseline and on the day of biopsy. The trial was closed early following an interim analysis and decision rule for futility and early stopping. Results: Complete data was available on 77 men with a mean age of 60.6 (IQR: 53.8 – 66.7). In the control group (no antibiotic; n=39), mean baseline and pre−biopsy PSA were 6.5 and 6.9 ng/ml, respectively (p=0.8). In men receiving antibiotic (n=38), mean baseline and pre−biopsy (post−antibiotic) PSA were 7.6 and 8.5 ng/ml, respectively (p=0.7). Prostate cancer was detected in 36 (47%) men. Detection rates did not significantly differ between individuals with an increasing PSA or decreasing PSA between the two measurements. Conclusions: Empiric use of antibiotics for an elevated PSA in an asymptomatic patient is not of clinical benefit.
Japanese cohort study of first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC) containing fluorouracil, oxaliplatin, and bevacizumab: EMERaLD study, first report.
Authors: Keisei Taku, Kou Ohata, Toraji Amano, Yasuo Ohashi, Kentaro Yamazaki, Masaya Watanabe, Shinsuke Satou, Takeshi Ooshima, Go Nishikawa, Hidekazu Hirano
Journal: Journal of Clinical Oncology (2013)

586 Background: An observational cohort study plays a crucial role to understand the current status of clinical practice and can be utilized as database for multi-purpose outcome research. Such database is available in Europe and the United States based on several cohort studies especially in mCRC, while there is no database available including treatments for mCRC patients in Japan. Methods: We planned and conducted a large cohort study to establish database available including treatments for mCRC patients. Major enrollment criteria included documented mCRC and first line CT containing fluorouracil, oxaliplatin and bevacizumab, started treatment in or after January 2010. The primary objectives are to evaluate overall survival(OS), liver metastasectomy rate (LMR), R0 liver resection rate (R0). The secondary objectives are progression-free survival, response rate (RR), and safety. We performed a preplanned interim analysis of 6-month efficacy and safety data after the 500th patient registration. Results: From October 2010 to September 2011, data from 1,353 patients were recruited from 132 centers in Japan, and we analyzed data on 538 patients of them. The background of 538 patients were as the following; male/female, 335/203; median age of 65 (range, 27-85); ECOG PS 0/1/2/3, 453/77/6/2; site of primary tumor colon/rectum/colorectal, 299/238/1; and site of metastatic disease liver/lung/others, 352/162/226; FOLFOX/ CapeOx/ others with bevacizumab, 234/290/14, KRAS-status wild/mutant/unknown, 131/88/319. 6-month efficacy and safety data were OS 97.5%, LMR 15.1%, R0 12.5%, RR 48.3%, G3/4(CTC-AEv4.0) related to bevacizumab; hypertension 1.5%, proteinuria 0.2%, thromboembolism 0.6%, bleeding 1.0%, and gastrointestinal perforation 1.3%. Conclusions: We have started the large Japanese cohort study which investigates first line CT for mCRC. We performed a preplanned interim analysis on 538 patients and there was no difference from past reports. We will further investigate and analyze 2-year efficacy and safety data on all 1,353 patients. This study is sponsored by the Public Health Research Center Foundation CSPOR in Japan. Clinical trial information: UMIN000006392.
Sickle Cardiomyopathy
Authors: Melissa C Caughey, Kenneth I Ataga, Alan L Hinderliter
Journal: JACC. Cardiovascular imaging (2016)

Of the known cardiac manifestations of sickle cell disease (SCD), none has received more attention than pulmonary hypertension. Elevated tricuspid regurgitant jet velocities (TRVs), even those too mild to be considered diagnostic of pulmonary hypertension, have been shown to predict mortality in
Abstract 2127: HnRNP Q1 contributes to tumorigenesis through the translational regulation of Aurora-A in colorectal cancer
Authors: Liang-Yi Hung
Journal: Cancer Research (2015)

Abstract HnRNP Q1 is a RNA-binding protein which belongs to hnRNP Q family and involves in pre-mRNA splicing, mRNA transport, translation and turnover. Data from Oncomine, which is a cancer microarray database, indicates that hnRNP Q1 is overexpressed in colorectal cancer. According the literatures, hnRNP Q1 can increase the translational efficiency through binding to the 5′-untranslated region (5′-UTR) of target genes. From RNA-IP assay following the next generation sequencing (NGS), we found that hnRNP Q1 regulates a group of cell cycle-related genes. Among them, Aurora-A is one of the targets of hnRNP Q1. Aurora-A is a cell-cycle dependent kinase involved in regulating centrosome duplication, maturation, and spindle assembly during mitosis. Abnormally elevated Aurora-A will cause mitotic defect and aneuploidy, which might lead to genomic instability and tumorigenesis. In addition, overexpression of hnRNP Q1 is positively correlated with overexpressed Aurora-A in clinical colorectal cancer tissues. Our previous report demonstrated that Aurora-A can be translational up-regulated in colorectal cancer. In this study, we demonstrated that hnRNP Q1 can bind to Aurora-A 5′-UTRs and also mapped the interacting domain between Aurora-A 5′UTR and hnRNP Q1 has been mapped by Biacore analysis, RNA-IP and biotin pull-down assay. Overexpressed hnRNP Q1 enhances the Aurora-A protein expression but doesn't alter its mRNA level. In contrast, repressed expression of hnRNP Q1 decreases the translation of Aurora-A. Importantly, we found that Aurora-A 5′UTR has IRES-dependent translational activity in a cell cycle regulated manner. Overexpression of hnRNP Q1 can up-regulate the IRES-dependent translation of Aurora-A during cell cycle progression, and promotes the cells proliferation. Taken together, our data indicate hnRNP Q1 is a novel trans-acting factor that binds on the Aurora-A 5′-UTRs and regulates it's translation, which may increase the cell proliferation and contribute to the tumorigenesis of colorectal cancer. Citation Format: Liang-Yi Hung. HnRNP Q1 contributes to tumorigenesis through the translational regulation of Aurora-A in colorectal cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2127. doi:10.1158/1538-7445.AM2015-2127